IL147642A0 - β-CARBOLINE DRUG PRODUCTS - Google Patents

β-CARBOLINE DRUG PRODUCTS

Info

Publication number
IL147642A0
IL147642A0 IL14764200A IL14764200A IL147642A0 IL 147642 A0 IL147642 A0 IL 147642A0 IL 14764200 A IL14764200 A IL 14764200A IL 14764200 A IL14764200 A IL 14764200A IL 147642 A0 IL147642 A0 IL 147642A0
Authority
IL
Israel
Prior art keywords
carboline
drug products
drug
products
carboline drug
Prior art date
Application number
IL14764200A
Other languages
English (en)
Original Assignee
Lilly Icos Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22520112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL147642(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Icos Llc filed Critical Lilly Icos Llc
Publication of IL147642A0 publication Critical patent/IL147642A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
IL14764200A 1999-08-03 2000-08-01 β-CARBOLINE DRUG PRODUCTS IL147642A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14704899P 1999-08-03 1999-08-03
PCT/US2000/020981 WO2001008688A2 (en) 1999-08-03 2000-08-01 Beta-carboline drug products

Publications (1)

Publication Number Publication Date
IL147642A0 true IL147642A0 (en) 2002-08-14

Family

ID=22520112

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14764200A IL147642A0 (en) 1999-08-03 2000-08-01 β-CARBOLINE DRUG PRODUCTS

Country Status (33)

Country Link
EP (1) EP1200092B1 (pl)
JP (1) JP4456788B2 (pl)
KR (1) KR20020063842A (pl)
CN (2) CN1377270A (pl)
AR (1) AR033953A1 (pl)
AT (1) ATE264680T1 (pl)
AU (1) AU773666B2 (pl)
BR (1) BR0012901A (pl)
CA (1) CA2380087C (pl)
CO (1) CO5200849A1 (pl)
CZ (1) CZ300151B6 (pl)
DE (1) DE60010089T2 (pl)
DK (1) DK1200092T3 (pl)
DZ (1) DZ3180A1 (pl)
EA (1) EA004302B9 (pl)
ES (1) ES2220506T3 (pl)
HK (1) HK1044278B (pl)
HR (1) HRP20020091B1 (pl)
HU (1) HU229443B1 (pl)
IL (1) IL147642A0 (pl)
MX (1) MXPA02001197A (pl)
MY (1) MY125428A (pl)
NO (1) NO321602B1 (pl)
NZ (1) NZ516613A (pl)
PE (1) PE20010480A1 (pl)
PL (1) PL199469B1 (pl)
PT (1) PT1200092E (pl)
SK (1) SK286365B6 (pl)
SV (1) SV2002000137A (pl)
TW (1) TWI235658B (pl)
UA (1) UA71629C2 (pl)
WO (1) WO2001008688A2 (pl)
ZA (1) ZA200200825B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1200090B1 (en) * 1999-08-03 2013-09-11 ICOS Corporation Pharmaceutical formulation comprising a beta-carboline and its use for treating sexual dysfunction
US8063214B2 (en) * 2004-10-28 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of tadalafil
US8865722B2 (en) 2006-01-05 2014-10-21 Teva Pharmaceutical Industries Ltd. Wet formulations of aripiprazole
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
DE102009035211A1 (de) 2009-07-29 2011-02-17 Ratiopharm Gmbh Copräzipitate umfassend einen Phosphodiesterase-5-Inhibitor (PDE-5-Inhibitor) und einen pharmazeutisch verträglichen Trägerstoff, ihre Herstellung und Verwendung
WO2012085927A2 (en) * 2010-12-02 2012-06-28 Mylan Laboratories, Limited Tadalafil compositions
WO2012095151A1 (en) 2010-12-23 2012-07-19 Zaklady Farmaceutyczne Polpharma Sa Solid pharmaceutical dosage forms comprising tadalafil and methods of preparation thereof
WO2012107090A1 (en) 2011-02-10 2012-08-16 Synthon Bv Granulated composition comprising tadalafil and a disintegrant
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
RU2013141446A (ru) 2011-02-10 2015-03-20 Синтон Бв Фармацевтическая композиция, содержащая тадалафил и циклодекстрин
JP5930686B2 (ja) * 2011-12-07 2016-06-08 株式会社トクヤマ 溶解性および安定性の向上した難溶性医薬品原体及びその製造方法
EP2826079B1 (de) 2012-03-15 2021-01-20 Merck Patent GmbH Elektronische vorrichtungen
WO2014003678A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
WO2014003677A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising solid dispersion particles containing tadalafil
CN105310984A (zh) * 2014-06-10 2016-02-10 合肥贝霓医药科技有限公司 一种pde5抑制剂的超微粉体及其制备方法
PL3111929T3 (pl) * 2014-06-24 2019-01-31 Wooshin Labottach Co., Ltd. Ulegający rozpadowi w jamie ustnej preparat w postaci błony zawierający tadalafil i sposób jego wytwarzania
SI3466951T1 (sl) 2014-07-23 2022-05-31 Krka, D.D., Novo Mesto Proces za pripravo zaviralca CGMP-fosfodiesteraze in oralne farmacevtske formulacije, ki obsega koprecipitate tadalafila
JP2016106139A (ja) * 2016-03-07 2016-06-16 株式会社トクヤマ 溶解性および安定性の向上した難溶性医薬品原体及びその製造方法
AU2018397436A1 (en) * 2017-12-26 2020-08-13 Ftf Pharma Private Limited Liquid oral formulations for PDE V inhibitors
ES2824818T3 (es) 2018-01-10 2021-05-13 Gap S A Cápsulas de gelatina blanda que comprenden una suspensión de tadalafilo
CN110638770B (zh) * 2019-10-25 2022-04-05 株洲千金药业股份有限公司 他达拉非片剂的制备方法及以该方法制得的片剂
WO2023227185A1 (en) * 2022-05-27 2023-11-30 Rontis Hellas S.A. Improved pharmaceutical composition containing tadalafil and nanomilling process for the preparation thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions

Also Published As

Publication number Publication date
CZ300151B6 (cs) 2009-02-25
NZ516613A (en) 2003-08-29
SK1722002A3 (en) 2002-05-09
DZ3180A1 (fr) 2001-02-08
PL353268A1 (pl) 2003-11-03
CA2380087A1 (en) 2001-02-08
PL199469B1 (pl) 2008-09-30
NO321602B1 (no) 2006-06-12
DE60010089D1 (de) 2004-05-27
EA004302B9 (ru) 2019-01-31
HU229443B1 (en) 2013-12-30
MY125428A (en) 2006-07-31
AR033953A1 (es) 2004-01-21
NO20020531D0 (no) 2002-02-01
HUP0202781A2 (hu) 2002-12-28
HRP20020091A2 (en) 2004-02-29
EP1200092B1 (en) 2004-04-21
CO5200849A1 (es) 2002-09-27
HRP20020091B1 (en) 2006-02-28
HUP0202781A3 (en) 2003-10-28
SV2002000137A (es) 2002-06-07
EP1200092A2 (en) 2002-05-02
TWI235658B (en) 2005-07-11
UA71629C2 (en) 2004-12-15
AU6508400A (en) 2001-02-19
HK1044278B (zh) 2004-10-08
JP4456788B2 (ja) 2010-04-28
MXPA02001197A (es) 2003-02-12
ZA200200825B (en) 2003-04-30
CA2380087C (en) 2007-05-01
HK1044278A1 (en) 2002-10-18
KR20020063842A (ko) 2002-08-05
ES2220506T3 (es) 2004-12-16
NO20020531L (no) 2002-04-03
WO2001008688A3 (en) 2001-08-16
DE60010089T2 (de) 2004-10-14
PT1200092E (pt) 2004-07-30
WO2001008688A2 (en) 2001-02-08
CN1377270A (zh) 2002-10-30
EA200200119A1 (ru) 2002-06-27
SK286365B6 (sk) 2008-08-05
DK1200092T3 (da) 2004-08-16
AU773666B2 (en) 2004-06-03
JP2003505510A (ja) 2003-02-12
CZ2002387A3 (cs) 2002-10-16
EA004302B1 (ru) 2004-02-26
CN101134019A (zh) 2008-03-05
PE20010480A1 (es) 2001-05-26
ATE264680T1 (de) 2004-05-15
BR0012901A (pt) 2002-04-16

Similar Documents

Publication Publication Date Title
IL147642A0 (en) β-CARBOLINE DRUG PRODUCTS
IL146632A0 (en) Pharmaceutical tablets
PL351686A1 (en) Novel pharmaceutical
HUP0203585A3 (en) Pharmaceutical combinations
EG23858A (en) Drug combination
EG23937A (en) Novel pharmaceutical
PL351135A1 (en) Novel pharmaceutical
IL146341A0 (en) Pharmaceutical complex
IL148543A0 (en) Pharmaceutical carrier formulation
EG23946A (en) Novel pharmaceutical
GB9909154D0 (en) Pharmaceutical formulation
GB9926251D0 (en) Pharmaceutical formulation
SI1200092T1 (en) Beta-carboline drug products
GB9923933D0 (en) Novel pharmaceutical
GB9907234D0 (en) Drug assay
GB9923934D0 (en) Novel pharmaceutical
CA85983S (en) Pharmaceutical container
CA88762S (en) Pharmaceutical tablet
GB9926437D0 (en) Pharmaceutical
GB9926434D0 (en) Pharmaceutical
GB9912195D0 (en) Novel pharmaceutical
GB9912196D0 (en) Novel pharmaceutical
GB9912197D0 (en) Novel pharmaceutical
GB9902593D0 (en) Drug combinations
GB9921064D0 (en) Drug combination

Legal Events

Date Code Title Description
NP Permission for amending the patent specification granted (section 66, patents law 1967)
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed